BFC Planning, Inc.’s CG Oncology CGON Stock Holding History

BFC Planning, Inc.’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$568	Hold	8	–	–	﹤0.01%	3236
2026 Q1	$541	Hold	8	–	–	﹤0.01%	2844
2025 Q4	$332	Buy	+8	New	+$331	﹤0.01%	2988

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFC Planning, Inc.'s CGON Position: Q2 2026 in Review

BFC Planning, Inc. held its CG Oncology (CGON) position steady in Q2 2026 at 8 shares worth $568. The position accounts for ﹤0.01% of the portfolio, ranked #3236.

BFC Planning, Inc. first reported a position in CGON in Q4 2025 and has held it in 3 quarters since. 229 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

BFC Planning, Inc. held 8 shares of CG Oncology worth $568 as of Q2 2026.
BFC Planning, Inc. left its CG Oncology share count unchanged in Q2 2026.
CG Oncology made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #3236 holding.
BFC Planning, Inc. first reported a position in CG Oncology in Q4 2025 and has held it in 3 quarters since.
229 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.